Bayer Exploring Sale of Diabetes Unit for Up to $2.5B

The transcript discusses Bayer's potential sale of its diabetes device business, with private equity firms like Cinven and Triton Advisors showing interest. The unit could be valued between €1 billion and 2 billion. Bayer is also planning to list its plastics unit on the stock market and is in the process of acquiring MERCS' over-the-counter drug business for $14 billion. Additionally, Bayer might be interested in acquiring Zoetis, an animal health company previously part of Pfizer.

What is the potential sale being discussed in relation to the diabetes device business?

Which private equity firms are mentioned as potentially interested in the sale?

What is the estimated value range for the unit that could be sold?

What significant acquisition is Bear planning in the healthcare sector?

Which company is mentioned as a potential target for acquisition in the animal health sector?